CAU
VRTX icon

Caxton Associates (UK)’s Vertex Pharmaceuticals VRTX Stock Holding History

Caxton Associates (UK)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-36,026
Closed -$16.1M – 984
2026
Q1 		$16.1M Buy
+36,026
New +$16.8M 0.36% 31

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Caxton Associates (UK)'s VRTX Position: Q2 2026 in Review

Caxton Associates (UK) sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 36,026 shares — an estimated $16.1M sold.

Caxton Associates (UK) first reported a position in VRTX in Q1 2026 and held it in 1 quarter. The position peaked at $16.1M in Q1 2026. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Caxton Associates (UK) reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 36,026 Vertex Pharmaceuticals shares in Q2 2026, an estimated $16.1M.
  • Caxton Associates (UK) first reported a position in Vertex Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Caxton Associates (UK)'s Vertex Pharmaceuticals position peaked at $16.1M in Q1 2026.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.